Il tuo browser è obsoleto

Con un browser aggiornato, l'esperienza di navigazione sul sito Web di Medtronic sarà migliore. Aggiorna il mio browser adesso.

×

Skip to main content

Novel AF Detection Cardiac Device Features

Overview

Approximately 20% of single chamber ICD patients may develop atrial fibrillation (AF) within the first 2 years of their ICD implant.1 This can lead to an increased risk of stroke and/or heart failure.2,3 Unfortunately, a significant number of AF episodes are asymptomatic and therefore missed when using standard intermittent monitoring techniques.4-9

Traditionally, single chamber ICDs have been unable to determine whether a patient is experiencing AF episodes due to the lack of an atrial lead — until now.

With this novel AF detection algorithm, you can now monitor, diagnose, and manage AF with a single, traditional lead and without electrodes in the atrium.

HOW IT WORKS

Atrial Fibrillation can conduct into the ventricle resulting in a variable heart rate, which can lead to variability in the timing of the R waves. Visia AF™ and Visia AF MRI™ monitor R-R variability and look for patterns, then determine if the variability and pattern are sufficient to meet the classification of AF.

This provides you the opportunity to determine if your patient has AF, quantify the time in AF, and determine if the ventricular rate is controlled. This information — combined with other patient factors — allows you to help manage your patients who have AF.

Visia AF and Visia AF MRI System Summary

Visia AF and Visia AF MRI ICD System Summary
1

Schloss EJ, et al. How Common is New Onset Atrial Fibrillation in Single Chamber ICD Patients? Sub-analysis from the PainFree SST Study. Presented at AHA 2015 (Abstract 17946).

2

Wolf PA, et al. Stroke. 1991;22:983-988.

3

Stewart S, et al. Am J Med. 2002;113:359-364.

4

Strickberger SA, Ip J, Saksena S, Curry K, Bahnson TD, Ziegler PD. Relationship between atrial tachyarrhythmias and symptoms. Heart Rhythm. February 2005;2(2):125-131.

5

Verma A, Champagne J, Sapp J, et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med. January 28, 2013;173(2):149-156.

6

Orlov MV, Ghali JK, Araghi-Niknam M, et al. Asymptomatic atrial fibrillation in pacemaker recipients: incidence, progression, and determinants based on the atrial high rate trial. Pacing Clin Electrophysiol. March 2007;30(3):404-411.

7

Quirino G, Giammaria M, Corbucci G, et al. Diagnosis of paroxysmal atrial fibrillation in patients with implanted pacemakers: relationship to symptoms and other variables. Pacing Clin Electrophysiol. January 2009;32(1):91-98.

8

Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia.Circulation. January 1994;89(1):224-227.

9

Ziegler PD, Koehler JL, Mehra R. Comparison of continuous versus intermittent monitoring of atrial arrhythmias. Heart Rhythm. December 2006;3(12):1445-1452.

Medtronic Italia S.p.A. Società a socio unico soggetta ad attività di direzione e coordinamento da parte di Medtronic PLC.
Cap. soc. € 1.200.487,00 - Codice fiscale, partita IVA e numero di iscrizione al Registro delle Imprese di Milano-Monza-Brianza-Lodi 09238800156 – REA MI – 1275682. Sede Legale e Uffici Via Varesina, 162 Edificio Raimondi - 20156 Milano.